Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 311

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 311
---

the following conditions are met:

| ● | the issuer of the securities                                        
 that was formerly a shell company has ceased to be a shell company; |

| ● | the issuer of the securities                                                         
 is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act; |

| ● | the issuer of the securities                                                                                                         
 has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter 
 period that the issuer was required to file such reports and materials) other than Form 8-K reports; and                             |

| ● | at least one year has elapsed                                                                                                    
 from the time that the issuer filed current Form 10-type information with the SEC reflecting its status as an entity that is not 
 a shell company.                                                                                                                 |

We are no longer a shell
company and, as a result, once the conditions set forth in the exceptions listed above are satisfied, Rule 144 will become available
for the resale of shares of Common Stock.

Registration Rights

Each of the Investor Rights
Agreement, the Keystone Registration Rights Agreements, the Arena Purchase Agreement, the Fee Modification Agreements and the Liquidated
Damages Modification Agreement provides for certain registration rights. For additional information, see the subsections entitled “Description of Securities—Registration Rights.”

<div align='center'>183

PLAN OF DISTRIBUTION</div>

We have engaged A.G.P./Alliance
Global Partners, or the placement agent, to act as our exclusive placement agent to solicit offers to purchase the shares of
our Common Stock, Pre-Funded Warrants and Offered Common Warrants offered by this prospectus pursuant to a placement agency
agreement. The placement agent may retain sub-agents and selected dealers in connection with this offering. We entered into a securities
purchase agreement directly with the purchasers who agreed to purchase our securities in this offering. In addition to rights and remedies
available to all purchasers in this offering under federal securities and state law, the purchasers will also be able to bring claims
of breach of contract against us.

The nature of the representations,
warranties and covenants in the placement agency agreement include:

| ● | standard                                                                                             
 issuer representations and warranties on matters such as organization, qualification, authorization, 
 no conflict, no governmental filings required, current in SEC filings, no litigation, labor          
 or other compliance issues, environmental, intellectual property and title matters and compliance    
 with various laws such as the Foreign Corrupt Practices Act;